Dr. Kevin Fahey Appointed to illumiSonics Board of Directors

LG Thin-Clients Feature Built-in RFID Capabilities Optimized for Use in Healthcare Facilities

Supporting its mission to help healthcare providers streamline operations and deliver exceptional patient care, LG Business Solutions USA introduced a new LG thin client...

Experien Group Acquired by Veranex

Veranex combines product development, regulatory, and market access expertise — globally and across complex and emerging markets.

February 10, 2021

illumiSonics Inc., is a medical tissue imaging company. Today they announced the appointment of Kevin Fahey, Ph.D., to the Board of Directors. The company has taken this action in anticipation of its growth and the commercial introduction of its proprietary Photo Acoustic Remote Sensing (PARS) tissue imaging platform.

Dr. Kevin Fahey brings new skills and will help strengthen the board of directors.

“Dr. Fahey brings commercial imaging domain expertise and industry-specific relationships to fully enable the power and unique capabilities of PARS as we fundamentally change the way the world looks at living tissue,” said Rocky Ganske CEO.

“PARS brings all of the valuable imaging of traditional photoacoustics, uniquely without the need for an interface. This capability opens several clinical applications not possible today with any other commercial imaging technology. We believe this creates a number of product and partnering opportunities for illumiSonics, and I am looking forward to participating,” said Dr. Fahey.

Dr. Fahey held executive positions at Xradia (acquired by ZEISS) and FEI (acquired by ThermoFisher), and at both large and small companies. In every case, he drove dramatic growth, creating new business lines and implementing integrated sales and marketing channels that drove rapid increases in sales. Dr. Fahey holds a Ph.D. in Materials Science and Engineering from Stanford University and a B.S. in Physics from the Massachusetts Institute of Technology.

illumiSonics’ proprietary PARS photoacoustic remote sensing technology is a revolution in optical imaging. Like traditional photoacoustic imaging, PARS measures optical absorption and is capable of providing functional and molecular imaging of anything that can absorb light. Traditional photoacoustic imaging has been constrained by the need to have contact with targeted tissues, the size of transducers and an inability to easily integrate with other optical imaging techniques. PARS is the first fully optical, non-contact photoacoustic imaging technology. This allows PARS to maintain all of the advantages of photoacoustic imaging while addressing its shortcomings, which provides incredible flexibility in how it can be deployed.

spot_img

DON'T MISS

Graham Belgrave Named to the 2021 PharmaVOICE 100 List of Distinguished Leaders

At Advanced Clinical, and from previous organizations, Belgrave serves as a mentor to several colleagues, where he challenges them to think outside of the box and take risks.

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.